Clinical Trials

At eFFECTOR, our passion is using the best science to develop better medicines to treat cancer. An important part of developing new treatments is conducting clinical trials. eFFECTOR is currently recruiting patients to be part of clinical trials to test potential new products.

Now Enrolling

A Study of Subjects Administered Anti-PD-1/Anti-PD-L1 Therapy that are experiencing Insufficient Response to Checkpoint Inhibitor Alone

Disease:
Non-small cell lung cancer, bladder cancer, head and neck cancer, hepatocellular cancer and others.

Phase 2 study is now enrolling.

More Info Clinical Trial

A Phase 2 Non-randomized Open-label Study Examining the Effect of eFT508 in Patients with Advanced Castrate-Resistant Prostate Cancer (CRPC)

Disease:
Castration-resistant prostate cancer (CRPC)

Phase 2 study is now enrolling.

More Info Clinical Trial